ribupatide
Sponsor Kailera Therapeutics, INC. · listed as KLRA
ribupatide is a drug asset sponsored by Kailera Therapeutics, INC., listed as KLRA. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Feb 2028 (month precision, medium confidence), tied to trial NCT07284875. That trial is in Phase 3 and currently recruiting, studying Obesity. It appears across 4 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for ribupatide
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2028-02-29 | READOUT | medium | NCT07284875 |
| 2028-03-27 | READOUT | medium | NCT07284901 |
Trials for ribupatide in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT07284875 catalyst | Phase 3 | Recruiting | 2028-02 | Experimental | Kailera | Obesity; Overweight |
| NCT07284979 | Phase 3 | Recruiting | 2028-03 | Experimental | Kailera | Obesity |
| NCT07284901 catalyst | Phase 3 | Recruiting | 2028-03-27 | Experimental | Kailera | Obesity With Diabetes; Overweight With Diabetes |
| NCT07709910 | Phase 3 | Not yet recruiting | 2028-11 | Experimental | Fujian Shengdi Pharmaceutical Co., Ltd. | Participants With Obesity and Knee Osteoarthritis |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More KLRA catalysts